Grace Blair S, Kennedy Sean E, Clayton Philip A, McDonald Stephen P
Australia and New Zealand Dialysis and Transplant Registry (ANZDATA), Level 9, East Wing, Royal Adelaide Hospital, Adelaide, South Australia, Australia,
Pediatr Nephrol. 2014 Jan;29(1):125-32. doi: 10.1007/s00467-013-2572-y. Epub 2013 Aug 9.
Transplantation is the preferred treatment for children with end-stage kidney disease (ESKD). Pre-emptive transplants, those from live donors and with few human leukocyte antigen (HLA) mismatches provide the best outcomes. Studies into disparities in paediatric transplantation to date have not adequately disentangled different transplant types.
We studied a retrospective cohort of 823 patients aged <18 years who started renal replacement therapy (RRT) in Australia 1990-2011, using the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). The primary outcomes were time to first kidney transplant and kidney donor type (deceased or living), analysed using competing risk regression.
Caucasian patients were most likely to receive any transplant, due largely to disparities in live donor transplantation. No Indigenous patients received a pre-emptive transplant. Indigenous patients were least likely to receive a transplant from a live donor (sub-hazard ratio 0.41, 95 % confidence interval 0.20-0.82, compared to Caucasians). Caucasian recipients had fewer HLA mismatches, were less sensitised and were more likely to have kidney diseases that could be diagnosed early or progress slowly.
Caucasian paediatric patients are more likely to receive optimum treatment--a transplant from a living donor and fewer HLA mismatches. Further work is required to identify and address barriers to live donor transplantation among minority racial groups.
移植是终末期肾病(ESKD)患儿的首选治疗方法。抢先移植,即来自活体供者且人类白细胞抗原(HLA)错配较少的移植,可提供最佳治疗效果。迄今为止,关于儿科移植差异的研究尚未充分区分不同的移植类型。
我们利用澳大利亚和新西兰透析与移植登记处(ANZDATA),对1990年至2011年在澳大利亚开始肾脏替代治疗(RRT)的823例18岁以下患者的回顾性队列进行了研究。主要结局为首次肾脏移植时间和肾脏供者类型(已故或活体),采用竞争风险回归进行分析。
白人患者最有可能接受任何类型的移植,这主要归因于活体供者移植方面的差异。没有原住民患者接受抢先移植。原住民患者接受活体供者移植的可能性最小(与白人相比,亚风险比为0.41,95%置信区间为0.20 - 0.82)。白人受者的HLA错配较少,致敏程度较低,且更有可能患有可早期诊断或进展缓慢的肾脏疾病。
白人儿科患者更有可能接受最佳治疗——来自活体供者的移植且HLA错配较少。需要进一步开展工作,以识别并消除少数种族群体在活体供者移植方面的障碍。